Chong Kun Dang targets Japanese market with domestically-first Nesp biosimilar
Chong Kun Dang(CEO Young-joo Kim) will target the Japanese market with ‘CKD-11101,’ a biosimilar of Nesp, the 2nd generation anemia treatment, which has been being developed for the first time in the domestic industry.
On the 5th, Chong Kun Dang announced establishment of the agreement to export...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
